4968: A study on how well CagriSema works in children and adolescence with excess body weight

• Research type

  Research Study

• Full title

  Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity

• IRAS ID

  1012353

• Contact name

  Clinical Transparency

• Contact email

  clinicaltrials@novonordisk.com

• Sponsor organisation

  Novo Nordisk A/S

• Eudract number

  2023-509176-42

• Clinicaltrials.gov Identifier

  NCT07253285

• Research summary

  Worldwide, the number of children with excess body weight has increased during the last decades. Excess body weight during childhood increases the risks of developing other diseases during adulthood. CagriSema is a medicine intended to help lose weight. This study will look at how CagriSema may help children with excess body weight (aged 8 to 17 years old) to lose weight. Additionally, diet and physical activity plans will be offered throughout the study.

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  25/LO/0567

• Date of REC Opinion

  30 Oct 2025

• REC opinion

  Further Information Favourable Opinion